NRx Pharmaceuticals (NASDAQ:NRXP) Issues Earnings Results, Misses Estimates By $0.35 EPS

Key Points

• NRx Pharmaceuticals reported quarterly EPS of $(0.44), missing the consensus estimate of $(0.09) by $0.35.
• Shares fell 2.1% to $3.27, trading within a 12-month range of $1.62 to $5.05.
• Analyst sentiment remains mixed but leans positive, with a consensus “Moderate Buy” rating and an average price target of $34.50; institutional investors own 4.27% of the stock.

NRx Pharmaceuticals (NASDAQ:NRXP - Get Free Report) announced its quarterly earnings data on Friday. The company reported ($0.44) EPS for the quarter, missing the consensus estimate of ($0.09) by ($0.35), reports.

NRx Pharmaceuticals Trading Down 2.1%

Shares of NASDAQ NRXP traded down $0.07 during mid-day trading on Friday, hitting $3.27. 1,124,669 shares of the stock traded hands, compared to its average volume of 1,198,563. NRx Pharmaceuticals has a twelve month low of $1.62 and a twelve month high of $5.05. The firm has a 50 day simple moving average of $3.82 and a two-hundred day simple moving average of $2.95.

Wall Street Analysts Forecast Growth

NRXP has been the topic of a number of research analyst reports. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of NRx Pharmaceuticals in a report on Wednesday, August 5th. Wall Street Zen upgraded NRx Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Sunday, June 14th. BTIG Research reduced their price objective on NRx Pharmaceuticals to $10.00 and set a "buy" rating on the stock in a research note on Friday, August 7th. D. Boral Capital reiterated a "buy" rating and issued a $34.00 target price on shares of NRx Pharmaceuticals in a research report on Tuesday, May 5th. Finally, HC Wainwright reissued a "buy" rating on shares of NRx Pharmaceuticals in a research note on Monday. Four investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, NRx Pharmaceuticals currently has a consensus rating of "Moderate Buy" and an average price target of $34.50.

Hedge Funds Weigh In On NRx Pharmaceuticals

Several large investors have recently bought and sold shares of the company. Anson Funds Management LP boosted its stake in shares of NRx Pharmaceuticals by 50.3% during the fourth quarter. Anson Funds Management LP now owns 3,043,957 shares of the company's stock valued at $8,249,000 after purchasing an additional 1,018,853 shares in the last quarter. State Street Corp increased its stake in shares of NRx Pharmaceuticals by 14.0% in the fourth quarter. State Street Corp now owns 86,984 shares of the company's stock valued at $236,000 after buying an additional 10,700 shares during the period. Commonwealth Equity Services LLC bought a new position in NRx Pharmaceuticals in the 4th quarter valued at approximately $994,000. Geode Capital Management LLC raised its holdings in NRx Pharmaceuticals by 17.8% in the 4th quarter. Geode Capital Management LLC now owns 218,866 shares of the company's stock valued at $593,000 after buying an additional 33,004 shares during the last quarter. Finally, Two Sigma Investments LP boosted its position in NRx Pharmaceuticals by 66.4% during the 3rd quarter. Two Sigma Investments LP now owns 52,332 shares of the company's stock worth $173,000 after buying an additional 20,880 shares during the period. 4.27% of the stock is currently owned by institutional investors.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company's research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx's pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source